Evidence map›Paper›PMID 26236991›Full record

ArticleNature medicine2015

Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.

Sara Lovisa, Valerie S LeBleu, Björn Tampe, Hikaru Sugimoto, Komal Vadnagara, Julienne L Carstens, Chia-Chin Wu, Yohannes Hagos, Birgitta C Burckhardt, Tsvetelina Pentcheva-Hoang and 4 more

Abstract read
In one paragraph

Article in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 569 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
569citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

569 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

509 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sara LovisaDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Valerie S LeBleuDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Björn TampeDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen, Germany.
Hikaru SugimotoDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Komal VadnagaraDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Julienne L CarstensDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-9914-0430
Chia-Chin WuDepartment of Genomic Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Yohannes HagosInstitute of Systemic Physiology and Pathophysiology, Göttingen University Medical Center, Georg August University, Göttingen, Germany.
Birgitta C BurckhardtInstitute of Systemic Physiology and Pathophysiology, Göttingen University Medical Center, Georg August University, Göttingen, Germany.
Tsvetelina Pentcheva-HoangDepartment of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Hersharan NischalDepartment of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
James P AllisonDepartment of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Michael ZeisbergDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen, Germany.
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PENNATHUR, SUBRAMANIAM · 2008 to 2022
$12.9M
TYPE IV COLLAGEN IN ALPORT SYNDROME PATHOGENESISR01DK055001 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 1999 to 2014
$4.3M
Role of Fibroblasts, Myeloid Cells and Matrix in PDACU01CA151925 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU, MOSES, HAROLD L · 2010 to 2014
$3.2M
Epigenetic Modifications in Renal FibrogenesisR01DK081576 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2009 to 2013
$1.8M
Targeting Pericytes in CancerR01CA155370 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2011 to 2015
$1.7M
NCI NIH HHS CA-016672NCI NIH HHS CA-151925NCI NIH HHS CA-155370NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS R01 CA155370NIDDK NIH HHS DK-081576NIDDK NIH HHS DK-55001NIDDK NIH HHS P30 DK081943NIDDK NIH HHS R01 DK055001NIDDK NIH HHS R01 DK081576
6 · The paper itself

Abstract

Kidney fibrosis is marked by an epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells (TECs). Here we find that, during renal fibrosis, TECs acquire a partial EMT program during which they remain associated with their basement membrane and express markers of both epithelial and mesenchymal cells. The functional consequence of the EMT program during fibrotic injury is an arrest in the G2 phase of the cell cycle and lower expression of several solute and solvent transporters in TECs. We also found that transgenic expression of either Twist1 (encoding twist family bHLH transcription factor 1, known as Twist) or Snai1 (encoding snail family zinc finger 1, known as Snail) expression is sufficient to promote prolonged TGF-β1-induced G2 arrest of TECs, limiting the cells' potential for repair and regeneration. In mouse models of experimentally induced renal fibrosis, conditional deletion of Twist1 or Snai1 in proximal TECs resulted in inhibition of the EMT program and the maintenance of TEC integrity, while also restoring cell proliferation, dedifferentiation-associated repair and regeneration of the kidney parenchyma and attenuating interstitial fibrosis. Thus, inhibition of the EMT program in TECs during chronic renal injury represents a potential anti-fibrosis therapy.

Indexed as

Cell Cycle CheckpointsEpithelial-Mesenchymal TransitionAnimalsAquaporin 1Cells, CulturedFibrosisG2 PhaseHumansKidneyMiceMice, Inbred BALB CMice, Inbred C57BLOrganic Anion Transport Protein 1Aquaporin 1Organic Anion Transport Protein 1

Identifiers

PMID26236991
PMCPMC4587560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.